In the wake of the increase in Current Liabilities in the second quarter 2025, Quick Ratio fell to 23.53 below Psyence Biomedical Ltd average.

Within Major Pharmaceutical Preparations industry 30 other companies have achieved higher Quick Ratio than Psyence Biomedical Ltd in second quarter 2025. While Quick Ratio total ranking in the second quarter 2025 has deteriorated compared to the prior quarter from to 215.

Explain Quick Ratio?
How much Cash & cash equivalents PBM�s has?
What are PBM�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PBM Quick Ratio	(Sep 30 2025) Q2	(Mar 31 2025) Q4	(Jan 31 2025) Q3	(Mar 31 2024) Q2	0 Q1
Y / Y Current Liabilities Change	-73.3 %	-70.71 %	-74.63 %	996.5 %	2352.71 %
Y / Y Cash & cash equivalent Change	269.98 %	736.78 %	-85.66 %	-23.9 %	219.17 %
Quick Ratio MRQ	23.53	74.95	0.38	0.73	1.7
PBM's Total Ranking	# 215	#	#	#	#
Seq. Current Liabilities Change	271.27 %	-70.71 %	-84.79 %	61.42 %	307.18 %
Seq. Cash & cash equivalent Change	16.54 %	5734.19 %	-92.12 %	-30.96 %	163.58 %

Quick Ratio second quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 31
Healthcare Sector	# 49
Overall Market	# 215

Quick Ratio Statistics
High	Average	Low
74.95	27.97	0.38
(Mar 31 2025)		(Jan 31 2025)

Financial Statements
Psyence Biomedical Ltd 's Current Liabilities	$ 0 Millions	Visit PBM's Balance sheet
Psyence Biomedical Ltd 's Cash & cash equivalent	$ 7 Millions	Visit PBM's Balance sheet
Source of PBM's Sales		Visit PBM's Sales by Geography

Cumulative Psyence Biomedical Ltd 's Quick Ratio

PBM's Quick Ratio for the trailling 12 Months

PBM Quick Ratio	(Sep 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Jan 31 2025) 12 Months	(Mar 31 2024) 12 Months	0 12 Months
Y / Y Current Liabilities TTM Growth	-6.86 %	109.18 %	159.49 %	107.69 %	37.41 %
Y / Y Cash & cash equivalent TTM Growth	185.78 %	148.53 %	17.02 %	15.18 %	47.61 %
Quick Ratio TTM	5.88	2.85	1.16	1.09	1.92
Total Ranking TTM	# 3953	#	#	#	#
Seq. Current Liabilities TTM Growth	-25 %	-5.59 %	-18.87 %	62.14 %	68.44 %
Seq. Cash & cash equivalent TTM Growth	54.88 %	131.59 %	-13.27 %	-8.14 %	34.69 %

Quick ratio ranking by company, industry and sector >> Back to PBM Financial Strength Comparisons >> Go to Compare PBM Quick Ratio to its Competitors

News about Psyence Biomedical ltd Quick Ratio

Psyence Group Strikes Strategic Debt-for-Equity Deal with Psyence Biomedical as Industry Dynamics Shift,

In a significant development that underscores the dynamic nature of the emerging psychedelic sector, Psyence Group Inc. (Psyence Group or the Company) has recently announced a debt-for-equity swap agreement with its NASDAQ-listed associate, Psyence Biomedical Ltd. (NASDAQ: PBM) (Psyence Biomed). This strategic maneuver, unveiled on October 14, 2024, reflects the Company’s adaptive approach amidst an evolving regulatory and investment landscape for psychedelic therapeutics.Under the terms of the Debt Swap Agreement, Psyence Biomed will issue 2,075,920 common shares to Psyence Group at a deemed price of US$0.50 each. This exchange aims to mitigate a portion of the debt obligation stemming from a promissory note issued in January 2024, coinciding with Psyence Biomed’s own NASDAQ listing. As part of the agreement, a significant contingency was established: should the average volume-weighted average price (VWAP) of the common shares fall below US$0.50 in the lead-up to January 15, 2025, Psyence Biomed is obliged to provide a make whole payment, either in cash or through additional common shares. Moreover, the company has pledged to register the resale of these shares within 60 days of issuance, facilitating liquidity for Psyence Group.

On the trailing twelve months basis PBM Cash & cash equivalent more than doubled by 269.98 % in Q2 2025 year on year, while Current Liabilities more than doubled to $0 millions, this led to increase in in Psyence Biomedical Ltd 's Quick Ratio to 5.88, Quick Ratio remained below PBM average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 30 other companies have achieved higher Quick Ratio than Psyence Biomedical Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from to 3953.

Explain Quick Ratio?
How much Cash & cash equivalents PBM�s has?
What are PBM�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 31
Healthcare Sector	# 49
Within the Market	# 3953

trailing twelve months Quick Ratio Statistics
High	Average	Low
74.95	27.97	0.38
(Mar 31 2025)		(Jan 31 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2025 MRQ Cash & cash equivalent	Sep 30 2025 MRQ Current Liabilities
Lb Pharmaceuticals Inc	53.15	$ 314.479 Millions	$ 5.917 Millions
Benitec Biopharma Inc	50.23	$ 94.534 Millions	$ 1.882 Millions
Monopar Therapeutics Inc	49.71	$ 127.677 Millions	$ 2.569 Millions
Curanex Pharmaceuticals Inc	46.70	$ 5.831 Millions	$ 0.125 Millions
Altimmune inc	43.88	$ 210.776 Millions	$ 4.804 Millions
Xbiotech Inc	41.34	$ 147.367 Millions	$ 3.565 Millions
Belite Bio Inc	36.61	$ 352.932 Millions	$ 9.641 Millions
Rapport Therapeutics Inc	35.84	$ 513.026 Millions	$ 14.316 Millions
Bright Minds Biosciences Inc	35.59	$ 63.669 Millions	$ 1.789 Millions
Janux Therapeutics Inc	35.54	$ 988.993 Millions	$ 27.831 Millions
Inhibitor Therapeutics Inc	34.01	$ 2.977 Millions	$ 0.088 Millions
Disc Medicine Inc	33.50	$ 615.920 Millions	$ 18.383 Millions
Roivant Sciences Ltd	32.77	$ 4,385.835 Millions	$ 133.857 Millions
Mbx Biosciences Inc	32.47	$ 391.673 Millions	$ 12.062 Millions
Upstream Bio Inc	31.28	$ 372.427 Millions	$ 11.908 Millions
Repare Therapeutics Inc	30.54	$ 112.604 Millions	$ 3.687 Millions
Keros Therapeutics Inc	28.78	$ 693.472 Millions	$ 24.092 Millions
Contineum Therapeutics Inc	28.68	$ 182.407 Millions	$ 6.361 Millions
Viking Therapeutics Inc	27.88	$ 714.570 Millions	$ 25.630 Millions
Liquidia Corporation	26.17	$ 157.496 Millions	$ 6.019 Millions
Edgewise Therapeutics inc	26.03	$ 563.340 Millions	$ 21.646 Millions
Prothena Corporation Public Limited Company	25.09	$ 330.843 Millions	$ 13.188 Millions
Immuneering Corporation	24.83	$ 227.563 Millions	$ 9.164 Millions
Psyence Biomedical ltd	23.53	$ 7.150 Millions	$ 0.304 Millions
Lava Therapeutics Nv	23.48	$ 99.364 Millions	$ 4.231 Millions
Trevi Therapeutics Inc	22.29	$ 194.927 Millions	$ 8.745 Millions
Ligand Pharmaceuticals Incorporated	21.76	$ 664.522 Millions	$ 30.539 Millions
Aprea Therapeutics Inc	21.39	$ 13.718 Millions	$ 0.641 Millions
Stoke Therapeutics Inc	21.34	$ 248.310 Millions	$ 11.634 Millions
Cervomed Inc	20.23	$ 27.294 Millions	$ 1.349 Millions

Date modified: 2026-07-07T12:30:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.